Health Catalyst (NASDAQ:HCAT – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Health Catalyst and Azenta”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $311.14 million | 0.28 | -$177.97 million | ($3.72) | -0.32 |
| Azenta | $593.82 million | 1.24 | -$55.76 million | ($3.96) | -4.05 |
Risk & Volatility
Health Catalyst has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Azenta has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Insider & Institutional Ownership
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 2.6% of Health Catalyst shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Health Catalyst and Azenta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -87.69% | -3.52% | -1.77% |
| Azenta | -30.49% | 1.23% | 1.02% |
Analyst Recommendations
This is a breakdown of current ratings for Health Catalyst and Azenta, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 1 | 8 | 4 | 0 | 2.23 |
| Azenta | 1 | 3 | 4 | 0 | 2.38 |
Health Catalyst currently has a consensus target price of $2.77, indicating a potential upside of 133.00%. Azenta has a consensus target price of $39.50, indicating a potential upside of 146.57%. Given Azenta’s stronger consensus rating and higher possible upside, analysts clearly believe Azenta is more favorable than Health Catalyst.
Summary
Azenta beats Health Catalyst on 10 of the 13 factors compared between the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
